Skip to content
Peptide research

SNAP-8

Also known as Acetyl Octapeptide-3
Category
Skin & Cosmetic
Administration routes
Topical
Regulatory status
Cosmetic ingredient

SNAP-8 is a synthetic octapeptide marketed as a needle-free topical Botox alternative, blocking SNARE-complex acetylcholine release at nerve endings. Human evidence is weak, drawn mainly from multi-peptide studies; superior-potency claims are untested. The main gap is durability and independence of evidence, not acute danger; risks are mild irritation, but long-term data are scarce. Sold as an FDA-regulated cosmetic ingredient, not an FDA-approved drug.

This is educational content compiled from published research, not medical advice. Always consult a licensed healthcare provider before using any peptide. Medical disclaimer

Compiled from published research indexed through March 2026.

Overview

SNAP-8 (Acetyl Octapeptide-3) is an eight-amino-acid peptide designed to smooth expression wrinkles — forehead lines, crow's feet, and frown lines — by reducing the chemical signal that tells facial muscles to contract. It is the more potent successor to Argireline (Acetyl Hexapeptide-8), with two extra amino acids that improve its wrinkle-reducing ability by about 30%. Like Argireline, it offers a topical, non-invasive alternative to Botox injections: it gently relaxes muscles without paralyzing them, without needles, and without systemic effects. Developed by Lipotec (now part of Lubrizol).

How it works in the body

An octapeptide (Acetyl Octapeptide-3) that inhibits the SNARE complex assembly needed for neurotransmitter release at facial nerve endings. By preventing vesicle fusion at the neuromuscular junction, it reduces acetylcholine release and the resulting muscle contractions that form wrinkles — a topical 'Botox-like' mechanism.

Research overview

SNAP-8 works by mimicking a piece of SNAP-25, a protein that is part of the molecular machinery (called the SNARE complex) that nerve cells use to release acetylcholine — the neurotransmitter that triggers muscle contraction. By occupying the same binding site without actually supporting the process, SNAP-8 jams the machinery and reduces acetylcholine release, softening muscle contractions. In the manufacturer's 28-day trial (17 women), 10% SNAP-8 solution reduced wrinkle depth by an average of 35% (with one subject reaching 63%), compared to 27% for Argireline and 3% for placebo. Together with Pentapeptide-18 (Leuphasyl), which calms nerve signaling through a different upstream mechanism, SNAP-8 showed synergistic effects: 47% inhibition of neurotransmitter release in manufacturer laboratory data summarized in a 2020 review. A 2024 microneedle patch study (24 subjects, 28 days) confirmed wrinkle improvement and improved skin elasticity with no adverse effects. Limitations include small study sizes (17-29 subjects), no large placebo-controlled trials isolating SNAP-8 alone, and limited long-term data.

Who researches SNAP-8?

Commonly researched by

  • People researching skin health and rejuvenation

    Studied for collagen synthesis, skin repair, or anti-aging skin effects.

Important considerations for

  • Those who are pregnant or breastfeeding

    Absolute

    No human reproductive safety data exists for this peptide. Effects on fetal development are unknown.

  • Anyone under 18

    Absolute

    No pediatric safety data. Not recommended for use in minors.

  • Those with Known hypersensitivity

    Absolute

    Discontinue immediately if allergic reaction occurs (rash, swelling, difficulty breathing).

Safety & interactions

General cautions

  • Pregnancy or breastfeeding

    Absolute

    No human reproductive safety data exists for this peptide. Effects on fetal development are unknown.

  • Children under 18

    Absolute

    No pediatric safety data. Not recommended for use in minors.

  • Known hypersensitivity

    Absolute

    Discontinue immediately if allergic reaction occurs (rash, swelling, difficulty breathing).

How to read the ratings

Benefits
= confidence in the evidence: High · Medium · Low · Speculative (High requires human randomized trials for that specific benefit)
Risks
= level of concern: High · Moderate · Low · Theoretical
Interactions
= direction with this peptide: Protective / Synergistic · Caution · Neutral

Risk summary(4)

Rated by level of concern

  • No known serious adverse effects

    Low

    PMID 39082657; PMID 31134751

  • Mild skin irritation or redness in sensitive individuals

    Low

    PMID 31134751 (no primary or cumulative skin reactions observed)

  • Limited long-term safety data

    Moderate

    PMID 31134751 (12 weeks); PMID 39082657 (28 days) — longest published exposures

  • Peptide instability and reduced efficacy under improper conditions

    Moderate

    General peptide-formulation stability principles; no acetyl octapeptide-3 stability study found in PubMed

Interaction summary(8)

Rated by direction with this peptide

  • Microneedling / dermarolling and dissolving microneedle patches

    SynergisticLow

    Stratum corneum bypass is the only route by which SNAP-8 has been shown to produce measurable clinical effect, and both published human trials used dissolving hyaluronic acid microneedle delivery — but the same barrier disruption raises the risk of irritation and of delivering co-formulated excipients not intended for intradermal exposure.

    PMID 39082657; PMID 31134751

  • Topical retinoids (tretinoin, adapalene, retinol)

    CautionLow

    Retinoid-induced barrier disruption and stratum corneum thinning increase peptide penetration but also compound irritation, and retinoid-typical acidic/oxidative vehicles can accelerate peptide degradation, so layering may increase erythema while reducing delivered active. Extrapolated from general retinoid tolerability and peptide chemistry; no SNAP-8-specific interaction study exists.

    Mechanistic/formulation inference; no published interaction study

  • Alpha- and beta-hydroxy acids (glycolic, lactic, salicylic acid)

    CautionLow

    Low-pH exfoliant vehicles both destabilize short peptides and strip the barrier, so co-application in the same routine step is likely to reduce SNAP-8 stability while raising irritation potential; separating application times is the standard mitigation. Inference from peptide pH stability, not from a study of this combination.

    Peptide pH-stability principles; no published interaction study

  • Botulinum toxin type A (onabotulinumtoxinA and related injectables)

    SynergisticTheoretical

    No interaction study exists for acetyl octapeptide-3. The one published real-world report of a neuro-cosmetic serum used alongside botulinum toxin type-A used 2% acetyl hexapeptide-8 plus dipeptide diaminobutyroyl in a multi-active vehicle, not SNAP-8. Adjunctive topical use between toxin sessions is common practice and no harm is expected, but SNAP-8 has not been shown to reach the neuromuscular junction from topical application, so any additive effect is unevidenced.

    PMID 39496132 (acetyl hexapeptide-8 serum + botulinum toxin type-A; does not study acetyl octapeptide-3)

  • Anionic surfactants and strongly ionic/high-electrolyte formulations

    CautionTheoretical

    This is a bioavailability/formulation-stability issue, not a health risk. Acetyl octapeptide-3 carries net charge and is prone to complexation and precipitation with anionic surfactants and at high ionic strength, a known incompatibility class for cationic and charged cosmetic peptides, but the supporting material is supplier handling guidance rather than peer-reviewed data.

    Peptide formulation chemistry; supplier handling guidance — no peer-reviewed study

  • Neuromuscular blocking agents and aminoglycoside antibiotics

    CautionTheoretical

    A SNARE-interfering peptide reaching systemic circulation could in principle add to presynaptic neuromuscular blockade, but topical application of a charged octapeptide produces negligible systemic exposure and no case reports or pharmacokinetic data support a real-world interaction.

    Mechanistic extrapolation only; no reported cases

  • Myasthenia gravis, Lambert-Eaton syndrome, and other neuromuscular junction disorders

    CautionTheoretical

    Manufacturers and clinicians sometimes advise avoidance by analogy to botulinum toxin contraindications, but this is precautionary reasoning about a mechanism that has never been shown to operate systemically after topical use, and no adverse events in this population have been reported.

    Precautionary extrapolation from botulinum toxin labeling; no SNAP-8 data

  • Other neuro-cosmetic peptides (acetyl hexapeptide-8/Argireline, pentapeptide-18/Leuphasyl, tripeptide-3/Syn-Ake)

    SynergisticTheoretical

    Co-formulation targeting complementary points in the acetylcholine-release pathway is standard industry practice and mechanistically coherent, but the supporting efficacy data are supplier-generated and no peer-reviewed combination trial with SNAP-8 was found.

    Supplier technical literature; PubMed returns no SNAP-8 combination trials

Known risks(4)

  • No known serious adverse effects

    Minimal

    All available studies (manufacturer testing and independent clinical studies) report excellent safety and tolerance. No cytotoxicity, genotoxicity, skin irritation, or systemic adverse effects have been observed in any published study. The peptide is applied topically at very low active concentrations (0.005% active at 10% solution incorporation) with minimal systemic absorption. Shin et al. (2024) reported no adverse effects in 24 subjects over 28 days. Draelos et al. (2016) reported no adverse events in 29 subjects over 14 weeks.

  • Mild skin irritation or redness in sensitive individuals

    Low

    Some individuals may experience mild, temporary irritation, tingling, or redness, particularly at higher concentrations (10% solution) or when SNAP-8 is combined with retinoids, vitamin C, or exfoliating acids. These effects are generally transient and resolve upon reducing concentration or frequency of application. A patch test is recommended for individuals with reactive or sensitive skin before full-face application.

  • Limited long-term safety data

    The longest published clinical study with SNAP-8 as an identified ingredient spans 14 weeks (Draelos et al. 2016, multi-peptide formulation). No studies have assessed safety of continuous daily application of SNAP-8 alone over years, which is how many consumers use anti-aging products. Long-term effects are unknown but considered low risk given the ingredient's topical application, trace active concentration, minimal systemic absorption, and decades of market use without safety signals.

  • Peptide instability and reduced efficacy under improper conditions

    Low (formulation risk, not safety risk)

    SNAP-8 is sensitive to heat (>40 degrees C), light, and pH extremes (optimal pH 4-7). Formulations stored improperly or mixed with incompatible ingredients (strong acids, high temperatures) may have degraded peptide with reduced efficacy. This is a product quality risk rather than a safety risk. Store products cool, away from direct light, and use formulations from reputable manufacturers.

Drug interactions(5)

  • No known pharmaceutical drug interactions (topical cosmetic use)

    SNAP-8 is a topical cosmetic ingredient applied at very low active concentrations (~0.005% active peptide at 10% solution incorporation) with minimal systemic absorption. No pharmaceutical drug interactions have been reported or are expected. It is not absorbed into the bloodstream in meaningful quantities and does not undergo hepatic metabolism or renal excretion at detectable levels.

  • Topical retinoids (tretinoin, retinol, adapalene)

    No adverse interaction, but potential for increased skin irritation when combined. SNAP-8 and retinoids have complementary mechanisms (neuromuscular modulation + collagen stimulation). However, retinoids can sensitize skin, and the combination may cause mild redness or irritation in sensitive individuals. Use at different times of day (SNAP-8 morning, retinoid evening) or introduce gradually to minimize irritation risk.

  • Topical exfoliating acids (glycolic acid, salicylic acid, lactic acid)

    Potential for reduced peptide efficacy and increased irritation. Strong acids (especially concentrated glycolic acid >10%) can destabilize the peptide structure and reduce SNAP-8 effectiveness. Low-pH formulations (<3) are incompatible with peptide stability. Apply acid-based products and SNAP-8 at separate times in the skincare routine, or use pH-buffered formulations.

  • Other topical neuromuscular peptides (Argireline, Leuphasyl/Pentapeptide-18, Syn-Ake)

    Synergistic (beneficial) interaction. SNAP-8 combined with Leuphasyl shows synergistic neurotransmitter inhibition (47% combined vs. 38% alone at equal concentrations). SNAP-8 combined with Argireline provides enhanced SNARE complex inhibition. These are intentional cosmetic combinations, not adverse interactions. Multi-peptide formulations are a standard cosmetic approach (Draelos et al. 2016).

  • Botulinum toxin injections (Botox, Dysport, Xeomin)

    Theoretical additive neuromuscular effect if topical SNAP-8 is used over areas treated with botulinum toxin injections. However, given the modest potency of topical SNAP-8 compared to injected botulinum toxin, clinically significant interaction is unlikely. Many cosmetic protocols use topical neuropeptide serums between Botox sessions to maintain results.

Research & benefits

Evidence base

Evidence Level
Moderate
Total Studies
8
Human Studies
4

The clinical evidence for SNAP-8 is consistent but limited in scope and rigor. The manufacturer's 28-day in-vivo study in 17 female volunteers is the primary efficacy data source, showing 34.98% mean wrinkle reduction (max -63.13%) at 10% solution, significantly outperforming Argireline (27.05%) and placebo (2.99%). A second manufacturer study at 3% solution showed up to 38% reduction. In vitro, SNAP-8 is approximately 30% more potent than Argireline (IC50 55 vs. 110 microM). Draelos et al. (2016) confirmed statistically significant facial line improvement in a 14-week multi-peptide trial. Shin et al. (2024) demonstrated wrinkle improvement and safety in a 24-subject microneedle delivery study. All studies report excellent safety with no adverse effects. However, there are no large-scale RCTs isolating SNAP-8, no long-term safety data beyond 28 days for the standalone ingredient, and core efficacy claims rest on manufacturer-sponsored data. The evidence is sufficient for cosmetic claims but far below pharmaceutical standards.

Researched for(6)

Rated by confidence in the evidence

  • Reduction of expression wrinkles (forehead lines, crow's feet, frown lines)

    Low

    Small human trials show eye-area improvement only; forehead and frown lines are unevidenced.

    PMID 39082657 (Ann Dermatol 2024, 24 subjects, placebo-controlled, periorbital); PMID 31134751 (J Cosmet Dermatol 2020, 12-week uncontrolled)

  • Superior potency compared to Argireline (Acetyl Hexapeptide-8)

    Speculative

    Claim comes from manufacturer data only; no peer-reviewed human comparison trial exists.

    PubMed search for "octapeptide-3": https://pubmed.ncbi.nlm.nih.gov/?term=%22octapeptide-3%22 — returns no comparative trial

  • Non-invasive Botox-like muscle relaxation without loss of facial expressivity

    Speculative

    Mechanism-based only; no human EMG or skin-penetration study confirms this effect.

    Mechanistic inference; no supporting human EMG or skin-penetration study identified in PubMed

  • Synergistic wrinkle reduction when combined with Leuphasyl (Pentapeptide-18)

    Speculative

    Mechanistically plausible, but no published trial has tested this specific combination.

    PMID 41722287 (pentapeptide-18 spectroscopic/computational, Comput Biol Chem 2026); PMID 42116636 (Vialox + Leuphasyl in silico/in vitro, Chem Biodivers 2026); PMID 39337562 (retinol + pentapeptide-18 SLN, IJMS 2024) — none test combination with acetyl octapeptide-3

  • Enhanced delivery via microneedle and nanoparticle systems

    Medium

    Two human studies evaluated multi-ingredient microneedle patches. Separate laboratory research also developed nanoparticles carrying acetyl octapeptide-3 itself; clinical superiority of those nanoparticles remains unproven.

    PMIDs 39082657 and 31134751: multi-ingredient microneedle studies. DOI 10.1007/s00289-022-04663-8: laboratory nanoparticle delivery of acetyl octapeptide-3.

  • Statistically significant facial line improvement in multi-peptide formulation

    Medium

    A 24-subject controlled trial showed significant eye-wrinkle improvement in a multi-ingredient formula.

    PMID 39082657 (Ann Dermatol 2024)

Benefits(6)

  • Reduction of expression wrinkles (forehead lines, crow's feet, frown lines)

    Lipotec manufacturer in-vivo study — 17 healthy female volunteers, 28 days, 10% SNAP-8 solution applied twice daily to periorbital area: 34.98% mean wrinkle depth reduction (max -63.13%), compared to 27.05% for 10% Argireline and 2.99% for placebo. Measured by silicon replica analysis with 3D confocal laser scanning microscopy. Second manufacturer study — split-face design, 3% SNAP-8 solution (0.05% active), 28 days, twice daily: up to 38% wrinkle depth reduction (mean 7.1%).

  • Superior potency compared to Argireline (Acetyl Hexapeptide-8)

    Lipotec in-vitro assay — SNAP-8 IC50 of 55 microM for catecholamine secretion inhibition vs. 110 microM for Argireline, confirming approximately 30% greater anti-wrinkle activity. Anti-wrinkle activity units (AAU): SNAP-8 = 0.0056 vs. Argireline = 0.0028. In-vivo comparison in 17 volunteers: SNAP-8 at 10% achieved 34.98% wrinkle reduction vs. 27.05% for Argireline at 10% over 28 days. Ji et al. 2020 (J Anal Sci Technol, DOI 10.1186/s40543-020-00232-8) noted that 'acetyl octapeptide-3 is an antiaging peptide that is more effective than acetyl hexapeptide-3.'

  • Non-invasive Botox-like muscle relaxation without loss of facial expressivity

    Lipotec manufacturer data and multiple reviews (PMC7662462, PMC11762834) — Unlike botulinum toxin injections, which irreversibly cleave SNARE proteins and paralyze muscles, SNAP-8 competitively inhibits SNARE complex formation, attenuating rather than abolishing muscle contraction. Applied topically, it preserves natural facial expressivity while reducing wrinkle depth. No muscle paralysis, facial drooping, or systemic effects reported in any study.

  • Synergistic wrinkle reduction when combined with Leuphasyl (Pentapeptide-18)

    Lipotec in-vitro data (summarized by Errante et al. 2020, PMC7662462) — At equal concentrations (0.75 mM each), SNAP-8 alone achieved 38% inhibition of neurotransmitter release, Leuphasyl alone achieved 7%, but the combination achieved 47% — demonstrating synergy. The mechanism is complementary: SNAP-8 blocks SNARE complex assembly (downstream), while Leuphasyl acts at enkephalin receptors to reduce neuronal excitability (upstream). This dual-mechanism approach parallels the Argireline + Leuphasyl combination marketed as Argirelox.

  • Enhanced delivery via microneedle and nanoparticle systems

    Shin et al. 2024 (Ann Dermatol, PMID 39082657) — Dissolving microneedle patch containing SNAP-8 and hyaluronic acid tested in 24 subjects over 28 days showed significant wrinkle improvement, reduced TEWL, enhanced skin elasticity and lifting, with no adverse effects. Baglamis et al. 2023 (Polymer Bulletin, DOI 10.1007/s00289-022-04663-8) — Glutamic-acid-containing nanoparticles achieved 220.69 mg/g adsorption capacity for SNAP-8, creating a non-toxic, efficient controlled-release system for improved anti-wrinkle delivery.

  • Statistically significant facial line improvement in multi-peptide formulation

    Draelos et al. 2016 (J Drugs Dermatol, PMID 27602972) — 14-week open-label clinical trial in 29 women with mild-to-moderate photodamage. Multi-peptide serum containing SNAP-8, Acetyl Hexapeptide-8, Pentapeptide-18, and other neuropeptides. Expert investigator found statistically significant improvement in facial lines, facial wrinkles, eye lines, and eye wrinkles at rest and at maximum smile. No adverse events reported.

Key studies(8)

  1. SNAP-8 Peptide Solution — In-Vivo Anti-Wrinkle Efficacy Study

    Manufacturer in-vivo study (controlled, not independently peer-reviewed)17 healthy female volunteers28 days, twice daily application to periorbital area

    Lipotec S.A. (Lubrizol)

    Manufacturer Technical Data Sheet

    2005

    Pivotal efficacy data for SNAP-8. 10% SNAP-8 solution: 34.98% mean wrinkle depth reduction (max -63.13%) in periorbital area. 10% Argireline solution: 27.05% mean reduction. Placebo: 2.99%. Measured by silicon imprint analysis with 3D confocal laser scanning microscopy. Established SNAP-8 as approximately 30% more effective than Argireline in vivo. No adverse effects reported.

  2. SNAP-8 Peptide Solution — Split-Face In-Vivo Efficacy Study (3% concentration)

    Manufacturer in-vivo study (split-face design)Female volunteers (exact number not disclosed)28 days, twice daily application

    Lipotec S.A. (Lubrizol)

    Manufacturer Technical Data Sheet

    2005

    Split-face study using cream containing 3% SNAP-8 solution (0.05% active Acetyl Octapeptide-3). Wrinkle depth reduced by up to 38% (mean 7.1%) in the treated half-face compared to untreated control. Confirmed dose-dependent efficacy at lower concentrations.

  3. An Open Label Clinical Trial of a Peptide Treatment Serum and Supporting Regimen Designed to Improve the Appearance of Aging Facial Skin

    Open-label clinical trial29 women with mild to moderately photodamaged skin14 weeks, twice daily application

    Draelos ZD, Kononov T, Fox T

    Journal of Drugs in Dermatology

    2016

    Multi-peptide serum containing SNAP-8 (Acetyl Octapeptide-3), Acetyl Hexapeptide-8, Pentapeptide-18, GABA, dipeptide diaminobutyroyl benzylamide diacetate, trifluoroacetyl tripeptide-2, and palmitoyl tetrapeptide-7. Expert investigator assessment found statistically significant improvement in facial lines, facial wrinkles, eye lines, and eye wrinkles at rest and at maximum smile compared to baseline. Improvements also in smoothness, softness, firmness, radiance, and luminosity. No adverse events.

  4. Ji M, Lee HS, Kim Y

    Journal of Analytical Science and Technology

    2020

    Developed and validated LC-MS/MS method for quantification of Acetyl Octapeptide-3 in cosmetic formulations, including biodegradable microneedle patches. Method showed good linearity (r >= 0.9971), LOQ of 0.0125 ng/mL, repeatability (RSD 0.02-0.12%), and accuracy (RE -1.68 to 1.44%). Validated SNAP-8 quantification in microneedle patches; comparative efficacy and botulinum-toxin statements were background claims, not outcomes tested in this study. Established analytical framework for quality control of SNAP-8 in advanced delivery systems.

  5. Errante F, Ledwoń P, Latajka R, Rovero P, Papini AM

    Frontiers in Chemistry

    2020

    Comprehensive review classifying SNAP-8 as a SNARE complex competitive inhibitor. Reported manufacturer data: 43% glutamate release inhibition at 1.5 mM, maximum wrinkle reduction of -62%, mean reduction of -35%. Documented synergistic interaction with Leuphasyl (Pentapeptide-18): SNAP-8 alone 38% inhibition, Leuphasyl alone 7%, combined 47% at equal concentrations (0.75 mM each).

  6. Baglamis S, Feyzioglu-Demir E, Akgol S

    Polymer Bulletin

    2023

    Synthesized glutamic-acid-containing nanoparticles for controlled release of Acetyl Octapeptide-3. Maximum adsorption capacity of 220.69 mg/g. Demonstrated non-toxic, efficient, and cost-effective nanocosmetic material with promise for anti-wrinkle treatment. Improved sustained release of SNAP-8 compared to conventional topical formulations.

  7. Clinical Safety and Efficacy Evaluation of a Dissolving Microneedle Patch Having Dual Anti-Wrinkle Effects With Safe and Long-Term Activities

    Comparative clinical study (split-face, placebo-controlled)24 subjects enrolled, 21 completed28 days (daily application for 14 days, then every 3 days for 14 days)

    Shin JY, Han DH, Yoon KY, Jeong DH, Park YI

    Annals of Dermatology

    2024

    Dissolving microneedle patch (DA-MNP) containing 0.03% SNAP-8, hyaluronic acid, L-ascorbic acid 2-glucoside, and sodium cyclic lysophosphatidic acid. Split-face design comparing DA-MNP vs. placebo MNP applied overnight to left and right periorbital areas. DA-MNP showed effective eye wrinkle improvement, reduced TEWL, enhanced skin elasticity and lifting compared to placebo. No adverse effects observed over 28 days. Microneedles measured 350 micrometers, achieving stratum corneum penetration.

  8. Pintea A, Manea A, Pintea C, Vlad RA, Birsan M, Antonoaea P, Redai EM, Ciurba A

    Biomolecules

    2025

    Classified SNAP-8 as a neurotransmitter inhibitor peptide that blocks the SNARE complex by inhibiting SNAP-25. Reported molecular weight of 1073.2 g/mol and amino acid sequence Glu-Glu-Met-Gln-Arg-Arg-Ala-Asp. Discussed nanosphere delivery systems as an alternative drug release approach to Botox treatment. Referenced the Shin et al. 2024 microneedle study demonstrating improved wrinkle treatment outcomes.

Regulation & availability

Why researchers look at it

In the manufacturer's 28-day trial (17 women), a 10% SNAP-8 solution reduced wrinkle depth by an average of 35%, with one subject reaching 63% reduction. A 2024 microneedle patch study (24 subjects) confirmed wrinkle improvement with no adverse effects. Together with Pentapeptide-18, which acts through a different upstream mechanism, a 2020 review reports 47% inhibition of neurotransmitter release in manufacturer laboratory data.

Estimated cost
$15-50/mo in OTC serums
FDA status
SNAP-8 (Acetyl Octapeptide-3) is a cosmetic ingredient marketed for topical cosmetic use, not an FDA-approved drug. Cosmetics generally do not require premarket approval, except for color additives, but manufacturers must substantiate safety and comply with applicable FDA requirements. A product that claims to treat a condition or change how the body works is regulated as a drug. CosIng lists ingredient information and functions; inclusion does not constitute EU approval. A related peptide's CIR assessment does not establish SNAP-8 safety. No approved drug product was identified; confidential NDA or IND submissions cannot be excluded from public records. It is registered in PubChem (CID 71587832).
WADA status
Not expressly named in the 2026 List. Absence from S2 does not exclude S0 coverage of unapproved pharmacological substances. Ingredient-specific clearance was not established; obtain an authoritative anti-doping determination.
Prescribability
No — SNAP-8 (Acetyl Octapeptide-3) is not a prescription drug. It is classified as a cosmetic ingredient, not a pharmaceutical agent, and is used exclusively in topical skincare formulations. It is regulated under cosmetics law (not drug law) in most jurisdictions and is not subject to pharmaceutical prescribing, dispensing, or compounding requirements.
Availability
SNAP-8 (Acetyl Octapeptide-3) is widely available as a cosmetic ingredient and in finished skincare products without a prescription. (1) Finished cosmetic products — Available in anti-aging serums, eye creams, and wrinkle-targeting treatments from numerous cosmetic brands worldwide. Often found in products alongside Argireline (Acetyl Hexapeptide-8) and other neuropeptides for synergistic effects. (2) Raw cosmetic ingredient recommended incorporation rate is 3-10% of the SNAP-8 solution in final formulations, added at the final stage of formulation below 40 degrees C to preserve peptide stability. Optimal pH range 4-7 for stability. It is a cosmetic ingredient, not a controlled substance or pharmaceutical drug.

International status

  • EU

    Available OTC in cosmetics (INCI listed)

  • US

    Available OTC in cosmetic products (not a drug)

  • Worldwide

    Regulated as cosmetic ingredient, not pharmaceutical

Regulatory timeline(10)

  1. 1993
    Sollner et al. identify the SNARE complex (SNAP-25, syntaxin, VAMP) as the core machinery for synaptic vesicle fusion, establishing the molecular target that SNAP-8 would later be designed to inhibit.
  2. 2002
    Lipotec S.A. (Barcelona, Spain) launches Argireline (Acetyl Hexapeptide-3/8), the first cosmetic peptide targeting the SNARE complex. Becomes the most commercially successful anti-wrinkle peptide.
  3. ~2005
    Lipotec develops SNAP-8 (Acetyl Octapeptide-3) by adding two amino acids (Ala, Asp) to the Argireline sequence, creating an octapeptide with approximately 30% greater potency. Conducts pivotal in-vivo studies in 17 volunteers showing 34.98% mean wrinkle reduction (max -63.13%) at 10% concentration.
  4. ~2005
    Lipotec conducts split-face in-vivo study with 3% SNAP-8 solution showing up to 38% wrinkle depth reduction. Publishes in vitro IC50 data (55 microM vs. 110 microM for Argireline).
  5. 2012
    Lubrizol Corporation (Berkshire Hathaway subsidiary) acquires Lipotec S.A. SNAP-8 continues under the Lubrizol Life Science - Beauty (Lipotec) portfolio.
  6. 2016-09
    Draelos et al. publish open-label 14-week clinical trial of multi-peptide serum containing SNAP-8 in Journal of Drugs in Dermatology (PMID 27602972). First independent peer-reviewed clinical data including SNAP-8.
  7. 2020
    Ji et al. publish LC-MS/MS analytical method for Acetyl Octapeptide-3 in Journal of Analytical Science and Technology, including application to biodegradable microneedle patches. Errante et al. review SNAP-8 mechanism and manufacturer assay data in Frontiers in Chemistry (PMC7662462).
  8. 2023
    Baglamis et al. publish nanoparticle controlled-release study for Acetyl Octapeptide-3 in Polymer Bulletin, demonstrating 220.69 mg/g adsorption capacity.
  9. 2024-04
    Shin et al. publish split-face placebo-controlled clinical study of dissolving microneedle patch containing SNAP-8 in Annals of Dermatology (PMID 39082657). 24 subjects, 28 days, demonstrating wrinkle improvement with no adverse effects.
  10. 2025
    Pintea et al. classify SNAP-8 as a neurotransmitter inhibitor peptide in comprehensive review of cosmeceutical peptides for skin senescence (Biomolecules, PMC11762834). Multiple review articles confirm SNAP-8's established role in anti-aging cosmetic science.

Sources & FAQs

Research sources(12)

Frequently asked questions(5)

How does SNAP-8 compare to Botox for wrinkle reduction?

SNAP-8 and Botox both target the neuromuscular junction to reduce expression wrinkles, but they work through fundamentally different mechanisms and have vastly different potencies. Botox (botulinum toxin) is injected and irreversibly cleaves SNARE proteins via enzymatic proteolysis, completely paralyzing targeted muscles for 3-6 months and achieving 80-90% wrinkle reduction. SNAP-8 is applied topically and competitively inhibits SNARE complex formation, producing a gentler attenuation of muscle contraction (35-63% wrinkle reduction at 10% solution in manufacturer studies). SNAP-8 advantages: no needles, no paralysis, preserved facial expressivity, no medical supervision required, continuous OTC availability. SNAP-8 is best suited for mild to moderate expression lines, prevention, or as maintenance between Botox sessions.

What concentration of SNAP-8 is needed for results?

The manufacturer (Lipotec/Lubrizol) recommends incorporating 3-10% of the SNAP-8 peptide solution into final formulations. The SNAP-8 solution typically contains 0.05% (500 ppm) active Acetyl Octapeptide-3 peptide, so a 10% incorporation rate yields ~0.005% active peptide in the finished product. The manufacturer's best results (34.98% mean, max -63.13% wrinkle reduction) were achieved at 10% solution concentration over 28 days. The 3% solution achieved up to 38% in a split-face study.

Is SNAP-8 the same as Argireline?

No, but they are closely related. Argireline (Acetyl Hexapeptide-8, also called Acetyl Hexapeptide-3) is a six-amino-acid peptide derived from the N-terminal region of SNAP-25. SNAP-8 (Acetyl Octapeptide-3) is an eight-amino-acid peptide created by appending alanine and aspartate to the Argireline sequence. Both were developed by Lipotec and both inhibit SNARE complex formation, but SNAP-8 is approximately 30% more potent (IC50 55 microM vs. 110 microM) and achieved higher wrinkle reduction in head-to-head testing (34.98% vs. 27.05% at 10% solution over 28 days). SNAP-8 is essentially the enhanced second-generation version of Argireline.

Is SNAP-8 safe for all skin types?

All available studies report excellent tolerance with no serious side effects. The Shin et al. (2024) microneedle study (24 subjects, 28 days) reported no adverse effects. The Draelos et al. (2016) multi-peptide trial (29 subjects, 14 weeks) reported no adverse events. Manufacturer safety testing showed no cytotoxicity or sensitization at recommended concentrations. However, individuals with sensitive skin may experience mild, temporary irritation or redness, particularly at higher concentrations (10%) or when combined with exfoliating acids or retinoids. A patch test is recommended before first use. Pregnancy and breastfeeding safety data are not available; consult a healthcare provider as a precaution.

How long does it take to see results with SNAP-8?

Based on manufacturer data and clinical studies: subtle improvements may be noticed within 1-2 weeks of consistent application (approximately 21% wrinkle reduction at 7 days in manufacturer testing). Measurable wrinkle depth reduction (35-63%) is typically achieved after 28 days at clinical-strength (10%) concentration. Optimal results are seen at 4-8 weeks. Effects are maintained with continuous use and gradually reverse within 2-4 weeks after discontinuation.